This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A look at the new data from the Phase 2 XPORT-MF-035 trial evaluating Karyopharm's selinexor in a heavily pretreated myelofibrosis population.

Ticker(s): KPTI

Who's the expert?

Institution: Vanderbilt University Medical Center

  • Assistant Professor of Medicine, Hematology/Oncology at Vanderbilt University Medical Center.
  • Manages 60 patients with Myelofibrosis.
  • Completed fellowship in experimental therapeutics from Taussig Cancer institute in 2021 and research focuses on cancer biology.

Interview Questions
Q1.

How would you describe the current treatment landscape for myelofibrosis, particularly in patients who have progressed on or are intolerant to JAK inhibitors?

Added By: sara_admin
Q2.

What are your impressions of the efficacy and safety data from the Phase 2 XPORT-MF-035 trial evaluating selinexor monotherapy in heavily pretreated myelofibrosis patients?

Added By: sara_admin
Q3.

In your view, where might selinexor fit into the treatment algorithm if approved—would it be more appropriate as a bridge therapy, salvage option, or earlier-line agent in specific patient subgroups?

Added By: sara_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.